



## Molecular Pathways in Metastasis of Lung Cancer

Guest Editor:

**Dr. Hanibal Bohnenberger**

Institute of Pathology, University  
Medical Center Göttingen,  
Robert-Koch-Straße 40, 37075  
Göttingen, Germany

Deadline for manuscript  
submissions:

**30 September 2024**


### Message from the Guest Editor

Dear Colleagues,

Lung cancer is the leading cause of cancer related death worldwide. In addition to the histological classification into mainly non-small cell adenocarcinomas and squamous cell carcinomas and small cell lung carcinomas, the growing understanding of oncogenic molecular pathways has led to a pronounced diversification of therapeutic options and thus to a significant improvement in the prognosis of patients. In particular, however, the pronounced tendency to develop distant metastases, especially in the brain, liver, bones and adrenal gland, severely limits the long-term prognosis of affected patients.

In this special issue, the molecular oncogenic pathways in lung cancer metastases will be highlighted from the perspective of basic, translational and clinical research with the overall goal of improving the use of existing therapeutics and identifying new potential drug targets.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)